C4 Therapeutics reported revenue of $6.64M and net income of -$23.76M for the quarter ended Jun 2026, up 2.8% year over year. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 8.50M | 20.08M | 7.65M | 13.83M | 6.75M | 2.85M | 3.76M | 2.66M | 11.07M | 3.26M | 3.04M | 12.01M | 15.36M | 5.18M | 7.24M | 6.46M | 11.23M | 11.02M | 6.15M | 6.64M | ||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 24.30M | 26.55M | 26.20M | 31.32M | 29.66M | 30.65M | 29.04M | 29.93M | 28.35M | 30.39M | 22.53M | 23.75M | 31.84M | 32.51M | 27.07M | 26.20M | 25.99M | 24.98M | 24.61M | 24.47M | ||||||||
| Selling, General & AdministrativeSG&A | 8.45M | 8.78M | 12.82M | 9.89M | 9.58M | 10.49M | 10.95M | 10.31M | 10.53M | 10.30M | 10.29M | 9.70M | 11.77M | 10.37M | 9.33M | 8.77M | 8.92M | 9.18M | 9.33M | 8.59M | ||||||||
| Restructuring CostsRestructuring | 2.44M | |||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | 10.73M | |||||||||||||||||||||||||||
| Operating ExpensesOpex | 32.75M | 35.33M | 39.02M | 41.22M | 39.24M | 41.15M | 39.99M | 40.23M | 38.88M | 40.69M | 35.26M | 33.45M | 43.61M | 42.89M | 36.40M | 34.96M | 45.64M | 34.16M | 33.94M | 33.06M | ||||||||
| Operating IncomeOp. Inc | -24.25M | -15.26M | -31.37M | -27.38M | -32.49M | -38.29M | -36.23M | -37.57M | -27.81M | -37.43M | -32.22M | -21.44M | -28.24M | -37.71M | -29.16M | -28.50M | -34.41M | -23.14M | -27.79M | -26.42M | ||||||||
| EBIT | -24.25M | -15.26M | -31.37M | -27.38M | -32.49M | -38.29M | -36.23M | -37.57M | -27.81M | -37.43M | -32.22M | -21.44M | -28.24M | -37.71M | -29.16M | -28.50M | -34.41M | -23.14M | -27.79M | -26.42M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | -0.09M | -0.62M | -2.88M | -0.93M | -0.83M | 1.27M | 1.67M | 0.70M | 0.87M | 0.78M | -0.25M | -0.06M | 0.90M | -0.40M | -0.01M | -0.07M | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.11M | 0.14M | 0.28M | 0.51M | 1.08M | 1.71M | 2.05M | 2.25M | 2.56M | 2.95M | 3.86M | 3.73M | 3.58M | 3.27M | 2.84M | 2.48M | 2.25M | 2.78M | 2.66M | 2.79M | ||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.62M | |||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.43M | -0.40M | -0.25M | -0.03M | 0.53M | 1.11M | 1.45M | 1.65M | 1.77M | 2.95M | 3.86M | 3.73M | 3.58M | 3.27M | 2.84M | 2.48M | 2.25M | 2.78M | 2.66M | 2.79M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -24.68M | -15.66M | -31.62M | -26.88M | -31.96M | -37.19M | -34.78M | -35.92M | -26.03M | -34.48M | -28.36M | -17.72M | -24.67M | -34.44M | -26.32M | -26.02M | -32.17M | -20.36M | -25.13M | -23.64M | ||||||||
| Tax ProvisionsTaxes | 1.00M | 0.28M | 0.13M | |||||||||||||||||||||||||
| Profit After TaxPAT | -24.77M | -16.28M | -31.62M | -27.41M | -32.79M | -35.91M | -34.78M | -35.92M | -27.04M | -34.76M | -28.36M | -17.72M | -24.67M | -34.57M | -26.32M | -26.09M | -32.17M | -20.49M | -25.13M | -23.76M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -24.68M | -15.66M | -31.62M | -26.88M | -31.96M | -37.19M | -34.78M | -35.92M | -27.04M | -34.75M | -28.36M | -17.72M | -24.67M | -34.57M | -26.32M | -26.02M | -32.17M | -20.36M | -25.13M | -23.64M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -24.68M | -15.66M | -31.62M | -26.88M | -31.96M | -37.19M | -34.78M | -35.92M | -27.04M | -34.75M | -28.36M | -17.72M | -24.67M | -34.57M | -26.32M | -26.02M | -32.17M | -20.36M | -25.13M | -23.64M | ||||||||
| Income towards Parent CompanyParent Net Inc | -24.68M | -15.66M | -31.62M | -26.88M | -31.96M | -37.19M | -34.78M | -35.92M | -27.04M | -34.75M | -28.36M | -17.72M | -24.67M | -34.57M | -26.32M | -26.02M | -32.17M | -20.36M | -25.13M | -23.64M | ||||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -24.68M | -15.66M | -31.62M | -26.88M | -31.96M | -37.19M | -34.78M | -35.92M | -27.04M | -34.75M | -28.36M | -17.72M | -24.67M | -34.57M | -26.32M | -26.02M | -32.17M | -20.36M | -25.13M | -23.64M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.51 | -0.34 | -0.65 | -0.55 | -0.65 | -0.76 | -0.71 | -0.73 | -0.55 | -0.70 | -0.41 | -0.26 | -0.35 | -0.50 | -0.37 | -0.37 | -0.44 | -0.25 | -0.20 | -0.18 | ||||||||
| EPS (Diluted) | -0.51 | -0.34 | -0.65 | -0.55 | -0.65 | -0.76 | -0.71 | -0.73 | -0.55 | -0.70 | -0.41 | -0.26 | -0.35 | -0.50 | -0.37 | -0.37 | -0.44 | -0.25 | -0.20 | -0.18 | ||||||||
| Shares Outstanding | 48.49M | 46.04M | 48.73M | 48.82M | 48.92M | 48.86M | 49.03M | 49.06M | 49.21M | 49.64M | 68.43M | 68.81M | 69.63M | 69.37M | 70.83M | 71.01M | 72.56M | 82.89M | 126.07M | 130.70M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 48.49M | 46.04M | 48.73M | 48.82M | 48.92M | 48.86M | 49.03M | 49.06M | 49.21M | 49.64M | 68.43M | 68.81M | 69.63M | 69.37M | 70.83M | 71.01M | 72.56M | 82.89M | 126.07M | 130.70M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 48.59M | 48.69M | 48.75M | 48.88M | 48.95M | 48.97M | 49.05M | 49.07M | 49.26M | 49.64M | 68.78M | 68.82M | 70.56M | 70.63M | 70.99M | 71.01M | 74.17M | 96.91M | 104.04M | 122.91M | ||||||||
| EBITDA | -24.25M | -15.26M | -31.37M | -27.38M | -32.49M | -38.29M | -36.23M | -37.57M | -27.81M | -37.43M | -32.22M | -21.44M | -28.24M | -37.71M | -29.16M | -28.50M | -34.41M | -23.14M | -27.79M | -26.42M | ||||||||
| Tax Rate | -3.85% | -0.80% | -0.38% |